ZURICH (Reuters) Mar 31 - Swiss drugmaker Roche Holding AG said the European Medicines Agency has removed a restriction on the label that prevented the use of Avastin in some patients whose cancer had spread to their brain.
Roche said the agency made its decision following a review of a number of analyses from clinical trials, as well as a safety database generated through use of Avastin over more than a decade.
Avastin is approved for the treatment of advanced-stage colorectal cancer, breast cancer, lung cancer and renal cell cancer.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου